InhaleRx Limited (ASX:IRX) Executes Study Order for Phase 2 IRX-211 Trial
Phase 2 Trial Execution
InhaleRx Limited has executed a Study Order with iNGENū CRO Pty Ltd to oversee its Phase 2 clinical trial of IRX-211 for Breakthrough Cancer Pain (BTcP) patients. The appointment, approved by shareholders, is fully funded by a $38.5 million facility with Clendon Biotech Capital. IRX-211 aims to provide a rapid-onset, non-opioid inhaled alternative for managing BTcP.
Executive Comments
IRX’s CEO, Darryl Davies, commented: “The execution of this Study Order for the IRX-211 Phase 2 trial represents a major milestone in our mission to provide cancer patients with a safe, effective, fast-acting therapy for breakthrough pain that does not further contribute to reliance on opioid-based medications.”
Next Steps
The study is set to commence as quickly as possible, with patient recruitment expected soon. The company is finalising batch manufacturing with its Sydney GMP manufacturer and will lodge an amendment with the Human Research Ethics Committee to accommodate the new sample size, likely consulting the FDA on these changes.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.